Diabetes & Endocrinology
Latest news
609 articles · 20 / page
Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with
GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
Thyroid Hormones May Offer a New Therapeutic and Prognostic Angle in ADPKD
Thyroid hormone signaling may influence ADPKD progression, with preclinical cyst suppression and patient biomarker associations suggesting prognostic and therapeutic potential.
Time-Restricted Eating vs Dietetic Guidance for Glycaemic Outcomes in Adults at Risk of Type 2 Diabetes
Time-restricted eating performed similarly to individualized dietetic guidance for short-term HbA1c change in adults at risk of type 2 diabetes, but non-inferiority was not confirmed at 12 months. Benefits were small, and adverse events wer
Gestational Diabetes and Later Cancer Risk: Reassuring Overall Results, but a Kidney Cancer Signal Emerges
A Danish registry study found no overall increase in selected cancers after gestational diabetes, but did observe a small absolute and relative increase in kidney cancer risk.
Publicly Funded Intermittently Scanned Continuous Glucose Monitoring Is Linked to Fewer Hospitalizations in Insulin-Treated Type 2 Diabetes
A large real-world study found that public implementation of intermittently scanned continuous glucose monitoring in insulin-treated type 2 diabetes was linked to better HbA1c, fewer acute diabetes hospitalizations, shorter stays, and lower
Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit
Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.
Restoring Cortisol Rhythm May Be Key to Recovery After Cushing Syndrome
In treated Cushing syndrome, normal late-night salivary cortisol was linked to better mood, quality of life, and metabolic outcomes, suggesting circadian cortisol restoration may be a meaningful recovery target.
Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
A Three-miRNA Plasma Signature May Help Detect Early Beta Cell Dysfunction Before Overt Type 2 Diabetes Progression
Plasma profiling identified a three-miRNA panel associated with beta cell rate sensitivity across glucose tolerance stages, suggesting a minimally invasive approach to detect early insulin secretory decline.
Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes
A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Based 5- and 10-Year Follow-Up After Two Clinical Trials
Long-term follow-up after two lifestyle trials found that reductions in visceral fat, more than overall weight loss, were linked to sustained cardiometabolic benefits and a lower risk of type 2 diabetes.
Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes
REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.
Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity
In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, end
Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure
A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.
Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study
The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.
Acromegaly Diagnosis
Acromegaly is often diagnosed late because symptoms are subtle. Serum IGF-I is the best screening test, OGTT confirms GH excess, and MRI localizes pituitary tumors. New AI and imaging tools may improve earlier detection.
An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide
A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.
Browse by specialty
Open language-specific specialty feeds and department pages.